Bio-Rad Launches Serology Assay for Detection of Coronavirus Antibodies

Bio-Rad Laboratories, Inc. (Hercules, CA, USA) has launched a blood-based immunoassay kit to identify antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19. Preliminary performance of the assay has been established and the kit is now undergoing clinical evaluation in several hospitals to further confirm its clinical performance. Initial data collected on more than 700 samples has demonstrated specificity of above 99%.

Bio-Rad develops, manufactures, and markets a broad range of innovative products for the life science research and clinical diagnostic markets. Its customers comprise university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Bio-Rad hasd recently launched a SARS CoV-2 Standard to support laboratory assay validation of coronavirus (COVID-19) testing through its Exact Diagnostics product line. Bio-Rad is providing the SARS CoV-2 Standard to help labs validate their COVID-19 assay results and accelerate access to testing.

Bio-Rad’s immunoassay kit detects total immunoglobulin (IgG, IgM, and IgA), an approach which appears to be more sensitive than assays against a single immunoglobulin. The test was designed for use manually or on an automated immunoassay platform, such as Bio-Rad’s EVOLIS System, which offers high throughput processing and sample traceability. Bio-Rad plans to offer the immunoassay kit globally. In the US, the company intends to use the FDA’s Emergency Use Authorization process to expedite US availability. Bio-Rad believes its blood-based immunoassay kit will help clinicians determine if an individual has been infected by the virus and therefore, has developed an immune response against SARS-CoV-2.

“Using a serology test to support the diagnosis of COVID-19 and to screen populations can provide a more complete understanding of infection rates as well as immunity,” said Dara Wright, Bio-Rad Clinical Diagnostics Group EVP & President. “The detection of antibodies to SARS-CoV-2 on a large scale may be used to guide public authorities in their decisions to lift partial or total containment orders according to the serological status of the population. Molecular and serology testing are highly complementary in this regard.”

Related Links:
Bio-Rad Laboratories, Inc.